When to Use the Pozzi Regimen in IgA Nephropathy
The Pozzi regimen should be used in patients with IgA nephropathy who have persistent proteinuria ≥1 g/day despite 3-6 months of optimized supportive care (maximally tolerated ACE inhibitor or ARB plus blood pressure control), and who have preserved kidney function with eGFR >50 ml/min per 1.73 m² 1, 2, 1.
Patient Selection Criteria
The Pozzi protocol is indicated when ALL of the following criteria are met:
- Proteinuria ≥1 g/day that persists after at least 90 days of maximal supportive therapy 1, 2, 3
- eGFR >50 ml/min per 1.73 m² at the time immunosuppression is being considered 1, 2
- Optimized supportive care has been maximized, including:
The Pozzi Regimen Protocol
The regimen consists of two components administered over 6 months 2:
- Intravenous methylprednisolone: 1 gram daily for 3 consecutive days at the beginning of months 1,3, and 5 2, 7
- Oral prednisone: 0.5 mg/kg on alternate days for the entire 6-month period 2, 7
This protocol demonstrated long-term benefit with 10-year renal survival of 97% versus 53% in untreated controls in the original Italian trial 2.
Absolute Contraindications to the Pozzi Regimen
Do NOT use the Pozzi regimen in patients with:
- eGFR <30 ml/min per 1.73 m² (unless rapidly progressive crescentic disease) 1, 2
- Uncontrolled diabetes or metabolic syndrome due to increased risk of serious infections and metabolic complications 3, 6
- Advanced age with frailty 3
- Obesity (increased toxicity risk) 3
- Latent infections including tuberculosis, HIV, hepatitis B or C 3
- Crescentic IgAN with >50% crescents (requires cyclophosphamide plus steroids instead) 1, 5
Special Populations and Alternative Approaches
For Chinese patients: Consider mycophenolate mofetil as a glucocorticoid-sparing alternative if steroids are contraindicated 3, 6
For Japanese patients: Tonsillectomy may be considered as an alternative approach, though this is not recommended in non-Japanese populations 3, 5
For patients with eGFR 30-50 ml/min per 1.73 m²: The risk-benefit ratio of corticosteroids becomes less favorable; maximal supportive care alone may be preferred 2, 4
Critical Pitfalls to Avoid
- Never initiate the Pozzi regimen without first optimizing supportive care for at least 3 months 1, 3, 4
- Do not use corticosteroids combined with cyclophosphamide or azathioprine in standard IgAN (only for crescentic disease) 1, 2
- Avoid immunosuppression in patients with advanced CKD (eGFR <30 ml/min per 1.73 m²) as toxicity outweighs benefit 1, 2, 4
- Do not overlook serious adverse event risk stratification before initiating therapy, particularly infection risk and metabolic complications 3, 6
Treatment Goals and Monitoring
The primary goal is proteinuria reduction to <1 g/day, which serves as a surrogate marker for improved kidney outcomes 2, 3, 4. Monitor:
- Proteinuria every 3 months during and after treatment 6
- eGFR every 3-6 months to assess kidney function trajectory 6
- Adverse effects including infections, glucose intolerance, and weight gain 2, 8
The Pozzi regimen achieved full clinical remission in 20% of patients versus 6% with supportive care alone, though it did not prevent GFR loss in all patients and was associated with substantial adverse events in some studies 8, 7.